{"id":19409,"date":"2025-02-02T10:11:00","date_gmt":"2025-02-02T10:11:00","guid":{"rendered":"https:\/\/www.nordicbioscience.com\/?p=19409"},"modified":"2025-08-26T12:39:31","modified_gmt":"2025-08-26T12:39:31","slug":"rheumatoid-awareness-day-2025-biomarkers-in-rheumatoid-arthritis","status":"publish","type":"post","link":"https:\/\/www.nordicbioscience.com\/blog\/rheumatoid-awareness-day-2025-biomarkers-in-rheumatoid-arthritis\/","title":{"rendered":"Rheumatoid Awareness Day 2025: Biomarkers in Rheumatoid Arthritis"},"content":{"rendered":"\n<p>Today is Rheumatoid Awareness Day, which we would like to honor by sharing one of our rheumatology teams&#8217; publications from 2024.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"639\" src=\"https:\/\/www.nordicbioscience.com\/wp-content\/uploads\/2025\/02\/knee-jpg-1024x639.webp\" alt=\"\" class=\"wp-image-27800\" srcset=\"https:\/\/www.nordicbioscience.com\/wp-content\/uploads\/2025\/02\/knee-jpg-1024x639.webp 1024w, https:\/\/www.nordicbioscience.com\/wp-content\/uploads\/2025\/02\/knee-jpg-300x187.webp 300w, https:\/\/www.nordicbioscience.com\/wp-content\/uploads\/2025\/02\/knee-jpg-768x479.webp 768w, https:\/\/www.nordicbioscience.com\/wp-content\/uploads\/2025\/02\/knee-jpg-1536x959.webp 1536w, https:\/\/www.nordicbioscience.com\/wp-content\/uploads\/2025\/02\/knee-jpg.webp 1540w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\"><em>Rheumatoid Awareness Day aims to spread awareness about this chronic autoimmune disease<\/em><\/figcaption><\/figure><\/div>\n\n\n<p><br><a href=\"https:\/\/www.nordicbioscience.com\/biomarker-solution\/rheumatology\/rheumatoid-arthritis\/\">Rheumatoid arthritis<\/a> is a chronic autoimmune disease characterized by inflammation in multiple articular joints, causing pain, joint damage, and loss in joint function. Despite the successful development of disease-modifying therapies, the heterogeneity of RA means that a significant proportion of patients respond poorly to treatment. Utilizing personalized and predictive biomarkers can optimize treatment efficacy, safety, and cost.<br><br>This study explored the link between type VI collagen breakdown and the effectiveness of Tocilizumab (toci), a drug used to treat <a href=\"https:\/\/www.nordicbioscience.com\/biomarker-solution\/rheumatology\/rheumatoid-arthritis\/\">rheumatoid arthritis (RA)<\/a>. By measuring a specific fragment of degraded type VI collagen (<a href=\"https:\/\/www.nordicbioscience.com\/biomarker-portfolio\/c6m\/\">C6M<\/a>), researchers found that toci treatment reduced C6M levels compared to placebo and that patients who responded well to TCZ showed a greater reduction in C6M. Additionally, lower initial decreases in <a href=\"https:\/\/www.nordicbioscience.com\/biomarker-portfolio\/c6m\/\">C6M<\/a> were associated with a lower likelihood of a good treatment response.<br><br>These findings suggest that quantifying type VI collagen turnover could help predict which <a href=\"https:\/\/www.nordicbioscience.com\/biomarker-solution\/rheumatology\/rheumatoid-arthritis\/\">RA<\/a> patients will benefit most from TCZ therapy, potentially leading to more personalized treatment approaches.<br><br><em>Article: Changes in type VI collagen degradation reflect clinical response to treatment in rheumatoid arthritis patients treated with tocilizumab<\/em><\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38167226\/\">Find the article here<\/a><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Today is Rheumatoid Awareness Day, which we would like to honor by sharing one of our rheumatology teams&#8217; publications from 2024. Rheumatoid arthritis is a chronic autoimmune disease characterized by inflammation in multiple articular joints, causing pain, joint damage, and loss in joint function. Despite the successful development of disease-modifying therapies, the heterogeneity of RA [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":19410,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[5191],"tags":[],"class_list":["post-19409","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2-minute-science"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nordicbioscience.com\/wp-json\/wp\/v2\/posts\/19409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nordicbioscience.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nordicbioscience.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nordicbioscience.com\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nordicbioscience.com\/wp-json\/wp\/v2\/comments?post=19409"}],"version-history":[{"count":5,"href":"https:\/\/www.nordicbioscience.com\/wp-json\/wp\/v2\/posts\/19409\/revisions"}],"predecessor-version":[{"id":28174,"href":"https:\/\/www.nordicbioscience.com\/wp-json\/wp\/v2\/posts\/19409\/revisions\/28174"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nordicbioscience.com\/wp-json\/wp\/v2\/media\/19410"}],"wp:attachment":[{"href":"https:\/\/www.nordicbioscience.com\/wp-json\/wp\/v2\/media?parent=19409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nordicbioscience.com\/wp-json\/wp\/v2\/categories?post=19409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nordicbioscience.com\/wp-json\/wp\/v2\/tags?post=19409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}